JP2021501183A - 二環式のスルホン及びスルホキシド、並びにその使用方法 - Google Patents
二環式のスルホン及びスルホキシド、並びにその使用方法 Download PDFInfo
- Publication number
- JP2021501183A JP2021501183A JP2020524177A JP2020524177A JP2021501183A JP 2021501183 A JP2021501183 A JP 2021501183A JP 2020524177 A JP2020524177 A JP 2020524177A JP 2020524177 A JP2020524177 A JP 2020524177A JP 2021501183 A JP2021501183 A JP 2021501183A
- Authority
- JP
- Japan
- Prior art keywords
- dihydro
- pyrrolo
- triazole
- fluoro
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 COC(C[C@@](c(cc1)cc(F)c1F)O*)=O Chemical compound COC(C[C@@](c(cc1)cc(F)c1F)O*)=O 0.000 description 2
- WBJBXWLZDZNZJW-RYUDHWBXSA-N CC(C)(C#N)S(c1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1)(=O)=O Chemical compound CC(C)(C#N)S(c1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1)(=O)=O WBJBXWLZDZNZJW-RYUDHWBXSA-N 0.000 description 1
- MWGGBZPAGIKAMH-QZSHFQNPSA-N CC(C)(C)S(c1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1)=O Chemical compound CC(C)(C)S(c1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1)=O MWGGBZPAGIKAMH-QZSHFQNPSA-N 0.000 description 1
- GQVULWOGMBFQRZ-QVCLKMBOSA-N CC(CC=C1F)([C@H](C[C@@H](c2n3)F)[n]2nc3S([C@H](C2)[C@@H]2F)(=O)=O)C=C1F Chemical compound CC(CC=C1F)([C@H](C[C@@H](c2n3)F)[n]2nc3S([C@H](C2)[C@@H]2F)(=O)=O)C=C1F GQVULWOGMBFQRZ-QVCLKMBOSA-N 0.000 description 1
- UIBIFMBOTZIONB-UCBNGSGESA-N CC1([C@H](C[C@@H](c2n3)F)[n]2nc3S(C(CO)(F)F)(=O)=O)C=CC=CC1 Chemical compound CC1([C@H](C[C@@H](c2n3)F)[n]2nc3S(C(CO)(F)F)(=O)=O)C=CC=CC1 UIBIFMBOTZIONB-UCBNGSGESA-N 0.000 description 1
- MAWXMDLEICESPX-MSYFUGIWSA-N CCCCC(CC)COC(CCSc1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1)=O Chemical compound CCCCC(CC)COC(CCSc1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1)=O MAWXMDLEICESPX-MSYFUGIWSA-N 0.000 description 1
- RHYFAPSWWDTTHB-KBPBESRZSA-N CCOC(C1(CS(c2n[n]([C@@H](C[C@@H]3F)c4ccccc4)c3n2)(=O)=O)CC1)=O Chemical compound CCOC(C1(CS(c2n[n]([C@@H](C[C@@H]3F)c4ccccc4)c3n2)(=O)=O)CC1)=O RHYFAPSWWDTTHB-KBPBESRZSA-N 0.000 description 1
- ZPTKBGCSXKQXCO-ZOBORPQBSA-N CCOC([C@H](C1)[C@@H]1Sc1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1)=O Chemical compound CCOC([C@H](C1)[C@@H]1Sc1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1)=O ZPTKBGCSXKQXCO-ZOBORPQBSA-N 0.000 description 1
- ZPTKBGCSXKQXCO-RFGFWPKPSA-N CCOC([C@H](C1)[C@H]1Sc1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1)=O Chemical compound CCOC([C@H](C1)[C@H]1Sc1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1)=O ZPTKBGCSXKQXCO-RFGFWPKPSA-N 0.000 description 1
- KTFGVGUADRGJGI-PTNGSMBKSA-N CCOC/C=C(\c1nc(Br)n[n]1C1OCCCC1)/c1ccccc1 Chemical compound CCOC/C=C(\c1nc(Br)n[n]1C1OCCCC1)/c1ccccc1 KTFGVGUADRGJGI-PTNGSMBKSA-N 0.000 description 1
- LJUZYKJUZIKFOS-IGHFXTMLSA-N C[C@@H](C1)c2nc(/S(/C(F)(F)F)=C\C)n[n]2[C@@H]1c(cccc1)c1Cl Chemical compound C[C@@H](C1)c2nc(/S(/C(F)(F)F)=C\C)n[n]2[C@@H]1c(cccc1)c1Cl LJUZYKJUZIKFOS-IGHFXTMLSA-N 0.000 description 1
- KHJCBTJJISKZPZ-IUCAKERBSA-N F[C@@H](C1)c2nc(S)n[n]2[C@@H]1c(cc1F)ccc1F Chemical compound F[C@@H](C1)c2nc(S)n[n]2[C@@H]1c(cc1F)ccc1F KHJCBTJJISKZPZ-IUCAKERBSA-N 0.000 description 1
- ZDELMEDCOLPGBI-RYUDHWBXSA-N F[C@@H](C1)c2nc(SC(C3)CC3(F)F)n[n]2[C@@H]1c1ccccc1 Chemical compound F[C@@H](C1)c2nc(SC(C3)CC3(F)F)n[n]2[C@@H]1c1ccccc1 ZDELMEDCOLPGBI-RYUDHWBXSA-N 0.000 description 1
- PSWSOAKNLQKMIW-VIFPVBQESA-N Fc1c([C@H](CCc2n3)[n]2nc3Br)cccc1 Chemical compound Fc1c([C@H](CCc2n3)[n]2nc3Br)cccc1 PSWSOAKNLQKMIW-VIFPVBQESA-N 0.000 description 1
- KDEZSZOJIGSNNQ-RYUDHWBXSA-N N#CC1(CC1)S(c1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1)(=O)=O Chemical compound N#CC1(CC1)S(c1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1)(=O)=O KDEZSZOJIGSNNQ-RYUDHWBXSA-N 0.000 description 1
- AUBQCLBTOSVRQA-PYJNHQTQSA-N N#C[C@H](C1)C[C@@H]1S(c1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1)(=O)=O Chemical compound N#C[C@H](C1)C[C@@H]1S(c1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1)(=O)=O AUBQCLBTOSVRQA-PYJNHQTQSA-N 0.000 description 1
- MGLDRWWWOALGNT-NOOOWODRSA-N NC([C@H](C1)[C@@H]1Sc1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1)=O Chemical compound NC([C@H](C1)[C@@H]1Sc1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1)=O MGLDRWWWOALGNT-NOOOWODRSA-N 0.000 description 1
- NTKDFUHUVGFVIL-UHFFFAOYSA-N O=C(c1nc(Br)n[n]1C1OCCCC1)c1ccccc1 Chemical compound O=C(c1nc(Br)n[n]1C1OCCCC1)c1ccccc1 NTKDFUHUVGFVIL-UHFFFAOYSA-N 0.000 description 1
- HWIUHIGUHUMVNA-IUCAKERBSA-N O=S(C(C(F)(F)F)(F)F)(c1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1)=O Chemical compound O=S(C(C(F)(F)F)(F)F)(c1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1)=O HWIUHIGUHUMVNA-IUCAKERBSA-N 0.000 description 1
- NOUKPAIFEWNYBL-DWBHSIJVSA-N O=S(C(C(F)(F)F)(F)F)c1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1 Chemical compound O=S(C(C(F)(F)F)(F)F)c1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1 NOUKPAIFEWNYBL-DWBHSIJVSA-N 0.000 description 1
- IQEFSLKSGODXCX-IUCAKERBSA-N O=S(C(F)(F)F)(c1n[n]([C@@H](C[C@@H]2F)c3cc(I)ccc3)c2n1)=O Chemical compound O=S(C(F)(F)F)(c1n[n]([C@@H](C[C@@H]2F)c3cc(I)ccc3)c2n1)=O IQEFSLKSGODXCX-IUCAKERBSA-N 0.000 description 1
- JAVCKHCONFBHSN-QWRGUYRKSA-N O=S(C1CC1)(c1n[n]([C@@H](C[C@@H]2F)c(cccc3F)c3F)c2n1)=O Chemical compound O=S(C1CC1)(c1n[n]([C@@H](C[C@@H]2F)c(cccc3F)c3F)c2n1)=O JAVCKHCONFBHSN-QWRGUYRKSA-N 0.000 description 1
- PJZUHFWOIATBCJ-GJZGRUSLSA-N O=S(c1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1)(c1ccccc1)=O Chemical compound O=S(c1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1)(c1ccccc1)=O PJZUHFWOIATBCJ-GJZGRUSLSA-N 0.000 description 1
- UAONBOVYJRVWMR-FPVGNUTFSA-N O=[S@@](C(F)F)c1n[n]([C@@H](CC2)c3cc(F)cc(F)c3)c2n1 Chemical compound O=[S@@](C(F)F)c1n[n]([C@@H](CC2)c3cc(F)cc(F)c3)c2n1 UAONBOVYJRVWMR-FPVGNUTFSA-N 0.000 description 1
- MCHJBVZXWQWPKL-VUPYVKPUSA-N O=[S@@](CF)c1n[n]([C@@H](C[C@@H]2F)c(cccc3)c3Cl)c2n1 Chemical compound O=[S@@](CF)c1n[n]([C@@H](C[C@@H]2F)c(cccc3)c3Cl)c2n1 MCHJBVZXWQWPKL-VUPYVKPUSA-N 0.000 description 1
- TVWAKDKIJBAIGC-GJPGNPISSA-N O=[S@@](CF)c1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1 Chemical compound O=[S@@](CF)c1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1 TVWAKDKIJBAIGC-GJPGNPISSA-N 0.000 description 1
- UAONBOVYJRVWMR-JLTPVHFHSA-N O=[S@](C(F)F)c1n[n]([C@@H](CC2)c3cc(F)cc(F)c3)c2n1 Chemical compound O=[S@](C(F)F)c1n[n]([C@@H](CC2)c3cc(F)cc(F)c3)c2n1 UAONBOVYJRVWMR-JLTPVHFHSA-N 0.000 description 1
- MCHJBVZXWQWPKL-QDDONVENSA-N O=[S@](CF)c1n[n]([C@@H](C[C@@H]2F)c(cccc3)c3Cl)c2n1 Chemical compound O=[S@](CF)c1n[n]([C@@H](C[C@@H]2F)c(cccc3)c3Cl)c2n1 MCHJBVZXWQWPKL-QDDONVENSA-N 0.000 description 1
- TVWAKDKIJBAIGC-ZPEMSAPTSA-N O=[S@](CF)c1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1 Chemical compound O=[S@](CF)c1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1 TVWAKDKIJBAIGC-ZPEMSAPTSA-N 0.000 description 1
- LFUVVIZZBVWRKN-RNJOBUHISA-N O[C@H](C1)C[C@H]1Sc1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1 Chemical compound O[C@H](C1)C[C@H]1Sc1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1 LFUVVIZZBVWRKN-RNJOBUHISA-N 0.000 description 1
- DMDZWSRUOABYNL-DTWKUNHWSA-N O[C@H](C1)c2nc(Br)n[n]2[C@@H]1c(cc1)cc(F)c1F Chemical compound O[C@H](C1)c2nc(Br)n[n]2[C@@H]1c(cc1)cc(F)c1F DMDZWSRUOABYNL-DTWKUNHWSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762579392P | 2017-10-31 | 2017-10-31 | |
| US62/579,392 | 2017-10-31 | ||
| PCT/EP2018/079772 WO2019086494A1 (en) | 2017-10-31 | 2018-10-30 | Bicyclic sulfones and sulfoxides and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021501183A true JP2021501183A (ja) | 2021-01-14 |
| JP2021501183A5 JP2021501183A5 (enExample) | 2021-12-09 |
Family
ID=64051580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020524177A Pending JP2021501183A (ja) | 2017-10-31 | 2018-10-30 | 二環式のスルホン及びスルホキシド、並びにその使用方法 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11072617B2 (enExample) |
| EP (1) | EP3704097B1 (enExample) |
| JP (1) | JP2021501183A (enExample) |
| KR (1) | KR20200083515A (enExample) |
| CN (1) | CN111278809B (enExample) |
| AR (1) | AR113811A1 (enExample) |
| AU (1) | AU2018360270A1 (enExample) |
| BR (1) | BR112020008446A2 (enExample) |
| CA (1) | CA3078688A1 (enExample) |
| CL (1) | CL2020001062A1 (enExample) |
| CO (1) | CO2020003475A2 (enExample) |
| CR (1) | CR20200168A (enExample) |
| IL (1) | IL273847A (enExample) |
| MA (1) | MA50503A (enExample) |
| MX (1) | MX2020003451A (enExample) |
| PE (1) | PE20211247A1 (enExample) |
| PH (1) | PH12020550537A1 (enExample) |
| RU (1) | RU2020115915A (enExample) |
| SG (1) | SG11202002877RA (enExample) |
| TW (1) | TW201922748A (enExample) |
| WO (1) | WO2019086494A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11071721B2 (en) | 2016-12-02 | 2021-07-27 | Genentech, Inc. | Bicyclic amide compounds and methods of use thereof |
| CN119613408A (zh) | 2017-07-14 | 2025-03-14 | 豪夫迈·罗氏有限公司 | 二环酮化合物及其使用方法 |
| MX2020003451A (es) | 2017-10-31 | 2020-08-03 | Hoffmann La Roche | Sulfonas y sulfoxidos biciclicos y metodos de uso de los mismos. |
| CN113302193B (zh) | 2019-01-11 | 2026-05-29 | 豪夫迈·罗氏有限公司 | 双环吡咯并三唑酮化合物及其使用方法 |
| TW202214617A (zh) | 2020-06-02 | 2022-04-16 | 法商賽諾菲公司 | 作為ｒｉｐｋ１抑制劑之異㗁唑啶及其用途 |
| CN118510775A (zh) | 2021-11-11 | 2024-08-16 | 建新公司 | 作为ripk1抑制剂的异噁唑烷及其用途 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR94123E (fr) * | 1965-07-23 | 1969-07-04 | Thomae Gmbh Dr K | Procédés pour fabriquer de nouvelles 4,5,6,7-tétrahydro-thiazolo[5,4-c]pyridines. |
| JPS62258385A (ja) * | 1986-04-30 | 1987-11-10 | シエ−リング・アグロケミカルズ・リミテツド | 除草剤 |
| WO2017004500A1 (en) * | 2015-07-02 | 2017-01-05 | Genentech, Inc. | Bicyclic lactams and methods of use thereof |
| WO2017096301A1 (en) * | 2015-12-04 | 2017-06-08 | Denali Therapeutics Inc. | Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (ripk 1) |
| WO2017136727A2 (en) * | 2016-02-05 | 2017-08-10 | Denali Therapeutics Inc. | Compounds, compositions and methods |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3948903A (en) | 1972-12-15 | 1976-04-06 | Parke, Davis & Company | Substituted N-(1,2-dihydro-2-oxonicotinyl)-cephalexins and -cephaloglycins |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| AU677216B2 (en) | 1992-07-27 | 1997-04-17 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Targeting of liposomes to the blood-brain barrier |
| US6080772A (en) * | 1995-06-07 | 2000-06-27 | Sugen, Inc. | Thiazole compounds and methods of modulating signal transduction |
| EP1007042A4 (en) | 1997-06-13 | 2001-07-04 | Sugen Inc | NEW HETEROCYCLIC COMPOUNDS FOR MODULATING THE PROTEIN-TYROSIN-ENZYME-RELATED CELLULAR SIGNAL TRANSDUCTION |
| JP2004502642A (ja) | 2000-02-11 | 2004-01-29 | ブリストル−マイヤーズ スクイブ カンパニー | カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用 |
| US6514221B2 (en) | 2000-07-27 | 2003-02-04 | Brigham And Women's Hospital, Inc. | Blood-brain barrier opening |
| AU2001286930A1 (en) | 2000-08-30 | 2002-03-13 | The Board Of Trustees Of The Leland Stanford Junior University | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| US7034036B2 (en) | 2000-10-30 | 2006-04-25 | Pain Therapeutics, Inc. | Inhibitors of ABC drug transporters at the blood-brain barrier |
| DE10121982B4 (de) | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung |
| CA2450073C (en) | 2001-07-25 | 2017-08-29 | Biomarin Pharmaceutical Inc. | Compositions and methods for modulating blood-brain barrier transport |
| US20030162695A1 (en) | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| PL382706A1 (pl) | 2002-08-26 | 2007-11-26 | Takeda Pharmaceutical Company Limited | Związek modulujący receptor wapnia i jego zastosowanie |
| JP4995423B2 (ja) | 2002-12-03 | 2012-08-08 | ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート | 物質を血液−脳関門を渡って輸送するための人工低密度リポタンパク質キャリア |
| ATE410161T1 (de) | 2003-05-02 | 2008-10-15 | Elan Pharm Inc | 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazol-3- carbonsäureamid-derivate und verwandte verbindungen als bradykinin b1 rezeptor antagonisten zur behandlung von entzündlichen erkrankungen |
| WO2005025511A2 (en) | 2003-09-10 | 2005-03-24 | Cedars-Sinai Medical Center | Potassium channel mediated delivery of agents through the blood-brain barrier |
| EP2083009A1 (de) | 2008-01-22 | 2009-07-29 | Grünenthal GmbH | Substituierte Tethrahydroimidazopyridin-Verbindungen und deren Verwendung in Arzneimitteln |
| US8299077B2 (en) | 2009-03-02 | 2012-10-30 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
| CN101824036A (zh) | 2009-03-05 | 2010-09-08 | 上海恒瑞医药有限公司 | 四氢咪唑并[1，5-a]吡嗪衍生物的盐,其制备方法及其在医药上的应用 |
| CA2852964A1 (en) | 2011-11-03 | 2013-05-10 | F. Hoffmann-La Roche Ag | Bicyclic piperazine compounds |
| JP6267193B2 (ja) | 2012-05-22 | 2018-01-24 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 置換ジピリジルアミン類及びそれらの使用 |
| MX2015009270A (es) | 2013-01-18 | 2015-10-30 | Hoffmann La Roche | Pirazoles sustituidos en posicion 3 y uso de los mismos como inhibidores de la cinasa cremallera de leucinas dual (dlk). |
| TWI648274B (zh) | 2013-02-15 | 2019-01-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 （二） |
| TWI710558B (zh) | 2013-05-01 | 2020-11-21 | 瑞士商赫孚孟拉羅股份公司 | 二雜芳基化合物及其用途 |
| RU2015147601A (ru) | 2013-05-01 | 2017-06-05 | Ф. Хоффманн-Ля Рош Аг | С-связанные гетероциклоалкилзамещенные пиримидины и их применения |
| AU2014287471C1 (en) | 2013-07-10 | 2019-11-28 | Vertex Pharmaceuticals Incorporated | Fused piperidine amides as modulators of ion channels |
| MX2016008110A (es) | 2013-12-20 | 2016-08-19 | Hoffmann La Roche | Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos. |
| CR20160418A (es) | 2014-03-26 | 2016-11-07 | Hoffmann La Roche | Nuevos compuestos biciclicos de 7 eslabones |
| RU2017109122A (ru) | 2014-08-21 | 2018-09-21 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Способы лечения с использованием гетероциклических амидов в качестве ингибиторов киназы |
| JP6701225B2 (ja) | 2015-03-09 | 2020-05-27 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 三環式ｄｌｋ阻害剤及びその使用 |
| UY36680A (es) | 2015-05-19 | 2016-12-30 | Glaxosmithkline Ip Dev Ltd | Amidas heterocíclicas como inhibidores de quinasa |
| US10751444B2 (en) | 2015-08-07 | 2020-08-25 | Victor Matthew Phillips | Flowable hemostatic gel composition and its methods of use |
| US10961258B2 (en) * | 2015-12-21 | 2021-03-30 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| AU2017356887B2 (en) | 2016-11-08 | 2022-06-30 | Cyclerion Therapeutics, Inc. | sGC stimulators |
| US11071721B2 (en) | 2016-12-02 | 2021-07-27 | Genentech, Inc. | Bicyclic amide compounds and methods of use thereof |
| US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| CN119613408A (zh) | 2017-07-14 | 2025-03-14 | 豪夫迈·罗氏有限公司 | 二环酮化合物及其使用方法 |
| WO2019072942A1 (en) | 2017-10-11 | 2019-04-18 | F. Hoffmann-La Roche Ag | BICYCLIC COMPOUNDS FOR USE AS INHIBITORS OF KINASE RIP1 |
| MX2020003451A (es) | 2017-10-31 | 2020-08-03 | Hoffmann La Roche | Sulfonas y sulfoxidos biciclicos y metodos de uso de los mismos. |
-
2018
- 2018-10-30 MX MX2020003451A patent/MX2020003451A/es unknown
- 2018-10-30 CR CR20200168A patent/CR20200168A/es unknown
- 2018-10-30 AR ARP180103157A patent/AR113811A1/es unknown
- 2018-10-30 US US16/175,206 patent/US11072617B2/en active Active
- 2018-10-30 MA MA050503A patent/MA50503A/fr unknown
- 2018-10-30 TW TW107138469A patent/TW201922748A/zh unknown
- 2018-10-30 KR KR1020207015138A patent/KR20200083515A/ko not_active Ceased
- 2018-10-30 JP JP2020524177A patent/JP2021501183A/ja active Pending
- 2018-10-30 AU AU2018360270A patent/AU2018360270A1/en not_active Abandoned
- 2018-10-30 BR BR112020008446-8A patent/BR112020008446A2/pt not_active Application Discontinuation
- 2018-10-30 SG SG11202002877RA patent/SG11202002877RA/en unknown
- 2018-10-30 PE PE2020000353A patent/PE20211247A1/es unknown
- 2018-10-30 RU RU2020115915A patent/RU2020115915A/ru unknown
- 2018-10-30 CA CA3078688A patent/CA3078688A1/en active Pending
- 2018-10-30 EP EP18796020.8A patent/EP3704097B1/en active Active
- 2018-10-30 WO PCT/EP2018/079772 patent/WO2019086494A1/en not_active Ceased
- 2018-10-30 CN CN201880070578.0A patent/CN111278809B/zh active Active
-
2020
- 2020-03-25 CO CONC2020/0003475A patent/CO2020003475A2/es unknown
- 2020-04-06 IL IL273847A patent/IL273847A/en unknown
- 2020-04-20 CL CL2020001062A patent/CL2020001062A1/es unknown
- 2020-04-30 PH PH12020550537A patent/PH12020550537A1/en unknown
-
2021
- 2021-06-06 US US17/340,082 patent/US12338241B2/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR94123E (fr) * | 1965-07-23 | 1969-07-04 | Thomae Gmbh Dr K | Procédés pour fabriquer de nouvelles 4,5,6,7-tétrahydro-thiazolo[5,4-c]pyridines. |
| JPS62258385A (ja) * | 1986-04-30 | 1987-11-10 | シエ−リング・アグロケミカルズ・リミテツド | 除草剤 |
| WO2017004500A1 (en) * | 2015-07-02 | 2017-01-05 | Genentech, Inc. | Bicyclic lactams and methods of use thereof |
| WO2017096301A1 (en) * | 2015-12-04 | 2017-06-08 | Denali Therapeutics Inc. | Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (ripk 1) |
| WO2017136727A2 (en) * | 2016-02-05 | 2017-08-10 | Denali Therapeutics Inc. | Compounds, compositions and methods |
Non-Patent Citations (3)
| Title |
|---|
| LIPSON, V. V. ET AL.: "Reactions of 3-amino-1,2,4-triazoles with cinnamic aldehydes", RUSSIAN CHEMICAL BULLETIN, INTERNATIONAL EDITION, vol. 58, no. 7, JPN6022041590, 2009, pages 1 - 4, ISSN: 0005052082 * |
| REGISTRY[ONLINE], JPN7022004672, ISSN: 0005052084 * |
| WALY, M. A. ET AL.: "A novel synthesis of imidazo[4,5-d]azepine ring system", POLISH J. CHEM., vol. 70, JPN6022041592, 1996, pages 296 - 301, ISSN: 0005052083 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3704097A1 (en) | 2020-09-09 |
| PH12020550537A1 (en) | 2021-03-22 |
| EP3704097C0 (en) | 2023-10-25 |
| CO2020003475A2 (es) | 2020-04-24 |
| CA3078688A1 (en) | 2019-05-09 |
| AU2018360270A1 (en) | 2020-03-26 |
| MX2020003451A (es) | 2020-08-03 |
| US20190127382A1 (en) | 2019-05-02 |
| WO2019086494A1 (en) | 2019-05-09 |
| IL273847A (en) | 2020-05-31 |
| TW201922748A (zh) | 2019-06-16 |
| EP3704097B1 (en) | 2023-10-25 |
| CR20200168A (es) | 2020-07-12 |
| RU2020115915A (ru) | 2021-12-01 |
| CN111278809B (zh) | 2024-06-25 |
| SG11202002877RA (en) | 2020-04-29 |
| AR113811A1 (es) | 2020-06-10 |
| US11072617B2 (en) | 2021-07-27 |
| KR20200083515A (ko) | 2020-07-08 |
| US12338241B2 (en) | 2025-06-24 |
| RU2020115915A3 (enExample) | 2022-05-06 |
| CN111278809A (zh) | 2020-06-12 |
| CL2020001062A1 (es) | 2020-08-21 |
| MA50503A (fr) | 2020-09-09 |
| PE20211247A1 (es) | 2021-07-13 |
| BR112020008446A2 (pt) | 2020-12-29 |
| US20230002391A1 (en) | 2023-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7398391B2 (ja) | Ｎ－［４－オキソ－２，３－ジヒドロ－１，５－ベンズオキサゼピン－３－イル］－５，６－ジヒドロ－４Ｈ－ピロロ［１，２－ｂ］ピラゾール－２－カルボキサミド誘導体及び例えば過敏性腸症候群（ＩＢＳ）を処置するためのＲＩＰ１キナーゼ阻害剤としての関連化合物 | |
| JP6890179B2 (ja) | 二環式アミド化合物及びその使用方法 | |
| JP7734163B2 (ja) | 二環式ケトン化合物及びその使用方法 | |
| US12338241B2 (en) | Bicyclic sulfones and sulfoxides and methods of use thereof | |
| JP7362600B2 (ja) | Ｒｉｐ１キナーゼ阻害剤として使用するための二環式化合物 | |
| US20250282788A1 (en) | Bicyclic ketone compounds and methods of use thereof | |
| RU2797922C2 (ru) | Бициклические кетоны и способы их применения | |
| HK40024493B (en) | Bicyclic sulfones and sulfoxides and methods of use thereof | |
| HK40024493A (en) | Bicyclic sulfones and sulfoxides and methods of use thereof | |
| HK40062362A (en) | Bicyclic pyrrolotriazolr ketone compounds and methods of use thereof | |
| HK40062362B (en) | Bicyclic pyrrolotriazolr ketone compounds and methods of use thereof | |
| HK40036919A (en) | Compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211027 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20211027 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220929 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221004 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230509 |